You have read all your free articles, to continue reading subscribe to read the rest of this content.
The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome (HES). HES is a group of rare, potentially fatal disorders characterised by high numbers of eosinophils in blood and tissues, which can cAlready a subscriber Login You have read all…
AstraZeneca and Merck have announced that the US Food and Drug Administration has granted Orphan Drug Designation (ODD) for selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1). “Neurofibromatosis type 1 is a devastating condition that can lead to life-threateniAlready a subscriber Login You have read…
Follicum's grant application to Vinnova to study binding of FOL peptides to receptors on pancreatic cells has been approved. Follicum is the coordinator of the project, which also includes Lund University and SARomics Biostructures. Parts of the project involve advanced analysis work to be perforAlready a subscriber Login You have…
The company receives close to 1 million SEK in a research grant from Swedish innovation agency, Vinnova, for developing a new treatment for genetic mitochondrial diseases. NeuroVive receives the grant from Vinnova's 2017 Swelife call to continue progressing the preclinical project NVP015. The cutAlready a subscriber Login You have read…
